Göbel, Sven http://orcid.org/0000-0002-2264-5569
Kortum, Fabian http://orcid.org/0000-0003-1387-1350
Chavez, Karim Jaén http://orcid.org/0000-0001-7129-8797
Jordan, Ingo http://orcid.org/0000-0003-2711-7252
Sandig, Volker
Reichl, Udo http://orcid.org/0000-0001-6538-1332
Altomonte, Jennifer http://orcid.org/0000-0003-1079-3633
Genzel, Yvonne http://orcid.org/0000-0002-2652-5943
Funding for this research was provided by:
Bundesministerium für Wirtschaft und Energie (#03EFOBY215)
Max Planck Institute for Dynamics of Complex Technical Systems (MPI Magdeburg)
Article History
Received: 23 February 2022
Revised: 9 May 2022
Accepted: 10 June 2022
First Online: 29 June 2022
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable.
: J. Altomonte (WO 2017/198779) holds a patent for the development and use of rVSV-NDV as an oncolytic therapy for cancer. I. Jordan and V. Sandig are employees of ProBioGen AG where AGE1.CR, AGE1.CR.pIX, and CD-U7 have been developed.